Andrea D'Alessandro

Leading the integration and the internationalization of the French VMS company NHCO after the acquisition by Chiesi Group.

• Global Strategic Plan CHC (NHCO plus local OTC products) 
• NHCO focus: definition of the global commercial strategy, FF sizing, POS & digital activities, pricing policies, brand story
• Operations & life cycle management: cross-functional team lead with Global Manufacturing, Regulatory, EU affiliates 
• Business Development: evaluation of external business opportunities in cooperation with Global BD
• Project lead: Governance model, Geographical expansion

Responsibility in the commercial governance of Top 5 EU countries.

• Budget & Forecast process, Annual sales target definition and monthly Business Review Meetings with affiliates
• Affiliates and Region EU Strategic Plans
• Analysis of affiliates' performance to identifiy the main growth drivers & barriers and define the proper commercial strategies (eg segmentation & targeting, bonus scheme, call plan)
• Ensure consistency of local strategy with corporate product guidelines (Respiratory, Neonatology, Transplant, CF)
• Ensure affiliates sustainable growth and profitability, in cooperation with Region Finance and HR teams
• Support Corporate functions and affiliates in the preparation and fine-tuning of Business Plans for BD activities
• Support Corporate functions in the preparation and fine-tuning of the Brand Plans for Corporate products

Leading the Muscle-Skeletal & Gastro portfolio (Rx, VMS and MD- 6 products) targeting Ortho and Gastro spec. BDG: 1,8M€ investment

• BDG/FCT sales & investments, gap analysis (sell in-out, Rx)
• Line Ext project lead for Muscle-Skeletal VMS (Darfax & Kalanit) with: market analysis and research, Advisory Boards, definition of product positioning, marketing plan
• KOLs management, scientific promotion materials, project management (eg CME, congresses)

Leading Pain & Respiratory portfolio (Rx & OTC- 4 products), targeting GPs, Ortho and Pharmacies. BDG: 2,5M€ investment

• Scientific promotion materials, project management (eg CME, congresses) for the Rx portfolio
• Pharmacy strategy for OTC products: seasonal TVC, commercial policies, targeting & POS activity (eg promo materials, displays) 
• Line Extension kick off for Women & Mens' Health brand Gx

Leading the relaunch of the brand Corlentor (SCAD and HF indications) in the hospital & retail market, following the Therapeutic Plan removal. BDG: 2,2M€ investment

• Scientific Promotion (visual aid & detailing scheme)
• CME/congresses planning and management
• Follow up at Hosp level of Post Marketing Observational Studies

Supporting the promotion of the pneumococcal vaccine Prevenar13.

• Scientific information specialist targeting GPs (sales-6 months)
• 6 months Marketing support (eg promo materials, mkt research)